Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Aug;72(2):307–311. doi: 10.1038/bjc.1995.329

P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo.

P De Angelis 1, T Stokke 1, L Smedshammer 1, R A Lothe 1, G Lehne 1, Y Chen 1, O P Clausen 1
PMCID: PMC2034003  PMID: 7640210

Abstract

Overexpression of the MDR1 product, P-glycoprotein (Pgp), has been shown to be one of the mechanisms underlying the development of multidrug resistance (MDR). Recently, one mutant p53 has been shown to stimulate the MDR1 gene promoter in vitro, whereas wild-type p53 repressed this activity. We measured Pgp and p53 expression by immunoblotting in 34 colorectal tumours, and performed mutation analyses on the p53-positive tumours to confirm the presence of mutant p53 protein. Tumour DNA indices (DIs) were also measured using flow cytometry. Pgp was detected in 44% (15/34) of the tumours and in 100% (13/13) of the normal mucosas (P = 0.0005), with highest levels of expression seen in normal mucosa, suggesting that initial drug resistance in colorectal tumours is not caused by Pgp. Highly DNA aneuploid tumours demonstrated the lowest levels of Pgp expression relative to moderately aneuploid and diploid colorectal tumours. p53 protein was detected in 53% (18/34) of the tumours, and 12 of 14 p53-positive tumours had p53 gene mutations, p53-negative tumours had approximately twice the level of Pgp expression of p53-positive tumours. Pgp expression was not associated with either p53 expression (P = 0.73) or incidence of p53 gene mutation (P = 0.70), suggesting that mutant p53 does not induce Pgp overexpression in colorectal carcinomas.

Full text

PDF
307

Images in this article

308Figure 1
on p.308

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauer K. D., Bagwell C. B., Giaretti W., Melamed M., Zarbo R. J., Witzig T. E., Rabinovitch P. S. Consensus review of the clinical utility of DNA flow cytometry in colorectal cancer. Cytometry. 1993;14(5):486–491. doi: 10.1002/cyto.990140506. [DOI] [PubMed] [Google Scholar]
  2. Børresen A. L., Hovig E., Smith-Sørensen B., Malkin D., Lystad S., Andersen T. I., Nesland J. M., Isselbacher K. J., Friend S. H. Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8405–8409. doi: 10.1073/pnas.88.19.8405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Carder P., Wyllie A. H., Purdie C. A., Morris R. G., White S., Piris J., Bird C. C. Stabilised p53 facilitates aneuploid clonal divergence in colorectal cancer. Oncogene. 1993 May;8(5):1397–1401. [PubMed] [Google Scholar]
  4. Chambers T. C., McAvoy E. M., Jacobs J. W., Eilon G. Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J Biol Chem. 1990 May 5;265(13):7679–7686. [PubMed] [Google Scholar]
  5. Chin K. V., Ueda K., Pastan I., Gottesman M. M. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science. 1992 Jan 24;255(5043):459–462. doi: 10.1126/science.1346476. [DOI] [PubMed] [Google Scholar]
  6. Clapper M. L., Hoffman S. J., Tew K. D. Glutathione S-transferases in normal and malignant human colon tissue. Biochim Biophys Acta. 1991 Apr 15;1096(3):209–216. doi: 10.1016/0925-4439(91)90007-v. [DOI] [PubMed] [Google Scholar]
  7. Cordon-Cardo C., O'Brien J. P., Boccia J., Casals D., Bertino J. R., Melamed M. R. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 1990 Sep;38(9):1277–1287. doi: 10.1177/38.9.1974900. [DOI] [PubMed] [Google Scholar]
  8. Danova M., Giordano M., Erba E., Palmeri S., Candiloro V., Riccardi A., Ucci G., Mazzini G., D'Incalci M., Ascari E. Flow cytometric analysis of multidrug-resistance-associated antigen (P-glycoprotein) and DNA ploidy in human colon cancer. J Cancer Res Clin Oncol. 1992;118(8):575–580. doi: 10.1007/BF01211799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dressler L. G., Bartow S. A. DNA flow cytometry in solid tumors: practical aspects and clinical applications. Semin Diagn Pathol. 1989 Feb;6(1):55–82. [PubMed] [Google Scholar]
  10. Fojo A. T., Ueda K., Slamon D. J., Poplack D. G., Gottesman M. M., Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A. 1987 Jan;84(1):265–269. doi: 10.1073/pnas.84.1.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fujii H., Tanigawa N., Muraoka R., Shimomatsuya T., Tanaka T. Detection of P-glycoprotein in solid tumors by flow cytometry. Anticancer Res. 1993 Nov-Dec;13(6A):2171–2175. [PubMed] [Google Scholar]
  12. Gill D. R., Hyde S. C., Higgins C. F., Valverde M. A., Mintenig G. M., Sepúlveda F. V. Separation of drug transport and chloride channel functions of the human multidrug resistance P-glycoprotein. Cell. 1992 Oct 2;71(1):23–32. doi: 10.1016/0092-8674(92)90263-c. [DOI] [PubMed] [Google Scholar]
  13. Goldstein L. J., Galski H., Fojo A., Willingham M., Lai S. L., Gazdar A., Pirker R., Green A., Crist W., Brodeur G. M. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst. 1989 Jan 18;81(2):116–124. doi: 10.1093/jnci/81.2.116. [DOI] [PubMed] [Google Scholar]
  14. Gros P., Ben Neriah Y. B., Croop J. M., Housman D. E. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature. 1986 Oct 23;323(6090):728–731. doi: 10.1038/323728a0. [DOI] [PubMed] [Google Scholar]
  15. Hamada H., Hagiwara K., Nakajima T., Tsuruo T. Phosphorylation of the Mr 170,000 to 180,000 glycoprotein specific to multidrug-resistant tumor cells: effects of verapamil, trifluoperazine, and phorbol esters. Cancer Res. 1987 Jun 1;47(11):2860–2865. [PubMed] [Google Scholar]
  16. Hultman T., Ståhl S., Hornes E., Uhlén M. Direct solid phase sequencing of genomic and plasmid DNA using magnetic beads as solid support. Nucleic Acids Res. 1989 Jul 11;17(13):4937–4946. doi: 10.1093/nar/17.13.4937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Jass J. R., Atkin W. S., Cuzick J., Bussey H. J., Morson B. C., Northover J. M., Todd I. P. The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology. 1986 May;10(5):437–459. doi: 10.1111/j.1365-2559.1986.tb02497.x. [DOI] [PubMed] [Google Scholar]
  18. Judson I. R. Understanding anticancer drug resistance: opportunities for modulation and impact on new drug design. Eur J Cancer. 1992;28(1):285–289. doi: 10.1016/0959-8049(92)90435-5. [DOI] [PubMed] [Google Scholar]
  19. Kramer R., Weber T. K., Morse B., Arceci R., Staniunas R., Steele G., Jr, Summerhayes I. C. Constitutive expression of multidrug resistance in human colorectal tumours and cell lines. Br J Cancer. 1993 May;67(5):959–968. doi: 10.1038/bjc.1993.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  21. Moorghen M., Cairns J., Forrester L. M., Hayes J. D., Hall A., Cattan A. R., Wolf C. R., Harris A. L. Enhanced expression of glutathione S-transferases in colorectal carcinoma compared to non-neoplastic mucosa. Carcinogenesis. 1991 Jan;12(1):13–17. doi: 10.1093/carcin/12.1.13. [DOI] [PubMed] [Google Scholar]
  22. Noonan K. E., Beck C., Holzmayer T. A., Chin J. E., Wunder J. S., Andrulis I. L., Gazdar A. F., Willman C. L., Griffith B., Von Hoff D. D. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A. 1990 Sep;87(18):7160–7164. doi: 10.1073/pnas.87.18.7160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Peters W. H., Boon C. E., Roelofs H. M., Wobbes T., Nagengast F. M., Kremers P. G. Expression of drug-metabolizing enzymes and P-170 glycoprotein in colorectal carcinoma and normal mucosa. Gastroenterology. 1992 Aug;103(2):448–455. doi: 10.1016/0016-5085(92)90833-k. [DOI] [PubMed] [Google Scholar]
  24. Pirker R., Wallner J., Gsur A., Götzl M., Zöchbauer S., Scheithauer W., Depisch D. MDR1 gene expression in primary colorectal carcinomas. Br J Cancer. 1993 Oct;68(4):691–694. doi: 10.1038/bjc.1993.411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Preudhomme C., Lepelley P., Vachee A., Soenen V., Quesnel B., Cosson A., Fenaux P. Relationship between p53 gene mutations and multidrug resistance (mdr1) gene expression in myelodysplastic syndromes. Leukemia. 1993 Nov;7(11):1888–1890. [PubMed] [Google Scholar]
  26. Redmond S. M., Joncourt F., Buser K., Ziemiecki A., Altermatt H. J., Fey M., Margison G., Cerny T. Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. Cancer Res. 1991 Apr 15;51(8):2092–2097. [PubMed] [Google Scholar]
  27. Smith-Sørensen B., Gebhardt M. C., Kloen P., McIntyre J., Aguilar F., Cerutti P., Børresen A. L. Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE). Hum Mutat. 1993;2(4):274–285. doi: 10.1002/humu.1380020407. [DOI] [PubMed] [Google Scholar]
  28. Ueda K., Cardarelli C., Gottesman M. M., Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A. 1987 May;84(9):3004–3008. doi: 10.1073/pnas.84.9.3004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Waxman D. J. Glutathione S-transferases: role in alkylating agent resistance and possible target for modulation chemotherapy--a review. Cancer Res. 1990 Oct 15;50(20):6449–6454. [PubMed] [Google Scholar]
  30. de Vries E. G., Pinedo H. M. Clinical implications of multidrug resistance to chemotherapy. Cancer Treat Res. 1991;57:171–186. doi: 10.1007/978-1-4615-3872-1_8. [DOI] [PubMed] [Google Scholar]
  31. de Waziers I., Cugnenc P. H., Berger A., Leroux J. P., Beaune P. H. Drug-metabolizing enzyme expression in human normal, peritumoral and tumoral colorectal tissue samples. Carcinogenesis. 1991 May;12(5):905–909. doi: 10.1093/carcin/12.5.905. [DOI] [PubMed] [Google Scholar]
  32. el Rouby S., Thomas A., Costin D., Rosenberg C. R., Potmesil M., Silber R., Newcomb E. W. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood. 1993 Dec 1;82(11):3452–3459. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES